Iconocast Logo

Welcome To Iconocast

How to add a URL link from your web site to the Iconocast web sites

Virtual tour of Southern California

 

Recent News and Articles on the Keywords: cognitive impairment + mild cognitive + donepezil  Related to the article below (Last Update: 7/8/2008)

Grillo: Mild cognitive impairment
Daily Camera, CO - Jun 30, 2008
Now people are mentioning "Mild Cognitive Impairment," which is new terminology for me. Can you please help me look this up? A. With the aging of America ...
Source: Google News

Vitamin E and Donepezil for the Treatment of Mild Cognitive Impairment -
RC Petersen, RG Thomas, M Grundman, D Bennett, R … - New England Journal of Medicine, 2005 - content.nejm.org
... Conclusions Vitamin E had no benefit in patients with mild cognitive impairment.
Although donepezil therapy was associated with a lower rate of progression to ...

Mild cognitive impairment in the elderly: predictors of dementia -
C Flicker - Neurology, 1991 - AAN Enterprises
... Goldman, T. Griesing, D. Kumar, and S. Richardson Efficacy of donepezil in mild
cognitive impairment: A randomized placebo-controlled trial Neurology, August 24 ...

Practice parameter: Early detection of dementia: Mild cognitive impairment (an evidence-based review … -
RC Petersen, JC Stevens, M Ganguli, EG Tangalos, … - Neurology, 2001 - AAN Enterprises
... Special Articles Practice parameter: Early detection of dementia: Mild cognitive
impairment (an evidence-based review). ... Mild cognitive impairment. ...

Efficacy of donepezil in mild cognitive impairment A randomized placebo-controlled trial -
S Salloway, S Ferris, A Kluger, R Goldman, T … - Neurology, 2004 - AAN Enterprises
... NEUROLOGY 2004;63:651-657 ? 2004 American Academy of Neurology Efficacy of donepezil
in mild cognitive impairment. A randomized placebo-controlled trial. ...

Natural history of mild cognitive impairment in older persons -
DA Bennett, RS Wilson, JA Schneider, DA Evans, LA … - Neurology, 2002 - AAN Enterprises
... Sano, CH van Dyck, LJ Thal, and the Alzheimer's Disease Cooperative Study Group
Vitamin E and Donepezil for the Treatment of Mild Cognitive Impairment N. Engl. ...

Prevalence of Neuropsychiatric Symptoms in Dementia and Mild Cognitive Impairment Results From the … -
CG Lyketsos, O Lopez, B Jones, AL Fitzpatrick, J … - JAMA, 2002 - Am Med Assoc
... Prevalence of Neuropsychiatric Symptoms in Dementia and Mild Cognitive Impairment
Results ... MCI indicates mild cognitive impairment. Table ...

Donepezil for cognitive impairment in Parkinson's disease: a randomised controlled study -
D Aarsland, K Laake, JP Larsen, C Janvin - British Medical Journal, 2002 - jnnp.bmj.com
... the prevalence of side effects of donepezil in patients ... of parkinsonism, and level
of cognitive impairment as measured ... of patients with PD and mild to moderate ...

… activity in hippocampus and frontal cortex of elderly subjects with mild cognitive impairment -
ST DeKosky, MD Ikonomovic, SD Styren, L Beckett, S … - Annals of Neurology, 2002 - doi.wiley.com
... NCI no cognitive impairment; MCI mild cognitive impairment; AD Alzheimer?s
disease; ANOVA analysis of variance; SD standard deviation. ...

Regional metabolic patterns in mild cognitive impairment and Alzheimer's disease A 1H MRS study -
K Kantarci, CR Jack, YC Xu, NG Campeau, PC O'Brien … - Neurology, 2000 - AAN Enterprises
... AD with MRI-based hippocampal volume in mild cognitive impairment. ... method for grading
the cognitive state of ... Donepezil?s effect on N-acetyl aspartate levels ...

Mild cognitive impairment -
S Gauthier, B Reisberg, M Zaudig, RC Petersen, K … - The Lancet, 2006 - Elsevier
... in the probability of progression from amnestic mild cognitive impairment to
Alzheimer's disease in patients allocated vitamin E or donepezil, compared with ...

Source: Google Scholar
 
 

Donepezil: no evidence to support the use for patients with mild cognitive impairment

 
 
Problems with memory which do not meet the diagnostic criteria for dementia, usually called mild cognitive impairment ( MCI ), can be the first sign of an impending dementia, particularly Alzheimer's disease.

There is no consensus on a definition or diagnostic criteria for MCI, and mild cognitive impairment remains a vague term and those so described are a heterogeneous population, consisting of people who may rapidly progress to dementia but also of people with stable cognitive deficits and some who may actually improve.

Donepezil ( Aricept, E2020 ), a cholinesterase inhibitor, has been shown to benefit all severities of Alzheimer's disease, including mild.

Researchers have assessed the effects of Donepezil in people with mild cognitive impairment but no diagnosis of dementia.

The trials were identified from a search of the Specialized Register of the Cochrane Dementia and Cognitive Improvement Group on 6 January 2006.

The two included studies, with a total of 782 patients, all with a MMSE (Mini-Mental State Examination ) greater than 23 points, identified similar patients for inclusion, but were quite different with respect to design and objective.
Pooling results in a meta-analysis was not possible.

In the first study the 13-item ADAS-Cog (Alzheimer’s Disease Assessment Scale - Cognitive subscale) showed benefit associated with 10 mg/day Donepezil compared with placebo at 24 weeks, but four other measures of cognitive function did not.
The analysis of withdrawals before the end of treatment at 24 weeks, withdrawals due to an adverse event, and numbers experiencing an adverse event, showed a significant difference between the Donepezil group and the placebo group in favour of placebo, ( 43/133 Donepezil 23/137 placebo, OR 2.37; p=0.003 ), ( 29/133 Donepezil 10/137 placebo, OR 3.54; p=0.001 ), ( 116/133 Donepezil, 100/137 placebo, OR 2.52; p=0.004 ). Various adverse effects were recorded, and several types of event, diarrhoea, nausea, vomiting, leg cramps and abnormal dreams, were reported more frequently in the Donepezil group compared with the placebo.

In the second study there was a significant difference between the number of patients diagnosed with Alzheimer's disease or another dementia between the Donepezil group and the placebo group in favour of Donepezil after one year of treatment ( 16/253 Donepezil 38/259 placebo ) ( OR 0.39; p=0.003 ), but no difference after 3 years of treatment ( 63/253 Donepezil 73/259 placebo ) ( OR 0.84; p=0.4 ).

Authors have concluded: “ There are two included studies. One study demonstrated a modest treatment effect in cognitive function as assessed by ADAS-Cog13 but not for other outcomes assessing different domains of cognitive function. Donepezil was associated with significantly more adverse effects compared with placebo, mostly gastrointestinal. From the second study, there is no evidence that Donepezil delays the onset of Alzheimer's disease. There is no evidence to support the use of Donepezil for patients with mild cognitive impairment. The putative benefits are minor, short lived and associated with significant side effects “.

Source: The Cochrane Database of Systematic Reviews, 2006
 
 
 
Google
Web www.iconocast.com
 
 
 

 

Continue News With: News4 ; News5 ; News6 ; News7 ; News8 ; News9 ; Nedws9A


ADVERTISEMENT

Iconocast is about learning and teaching without borders; we offer eMarketing, Internet Advertising, Internet Marketing, Search Engine Optimization, Search Engine Marketing, Online Branding, and eMarketing News Services. Home

 © 2002-2006

Keywords::

Contact Iconocast

Home Page